CV Sciences AI Stock Analysis
Want to see CVSI full AI Analyst Report?
CV Sciences (CVSI) AI Stock Analysis
CV Sciences
(Other OTC:CVSI)
The score is held down primarily by weak financial performance (sharp revenue contraction, persistent losses, and negative operating/free cash flow) and a bearish technical backdrop (price below key moving averages with negative MACD). Corporate events add some support via legal-overhang resolution and a small improvement in profitability metrics (positive adjusted EBITDA), but these are not yet enough to offset the broader deterioration. Valuation is difficult to justify on earnings due to the negative P/E and no dividend support.
CV Sciences (CVSI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.17M
- Dividend Yield
- ―
- Average Volume (3M)
- 635.13K
- Price to Earnings (P/E)
- -1.1
- Beta (1Y)
- 0.74
- Revenue Growth
- -12.88%
- EPS Growth
- -8.75%
- Country
- US
- Employees
- 43
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
CV Sciences Business Overview & Revenue Model
Company Description
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division fo...
How the Company Makes Money
CV Sciences makes money primarily by selling hemp-derived CBD consumer products (most notably under the PlusCBD brand). Revenue is generated through (1) wholesale/retail distribution, where CV Sciences sells products to retailers and distributors who...
CV Sciences Earnings Call Summary
The call presented a balanced picture: the company is making meaningful progress on cost reductions, working capital management and product/brand expansion (including a growing non‑cannabinoid line and DTC efforts) and has achieved modest positive operating cash flow. However, material top-line pressure (revenue down 7% QoQ and 17% YoY; unit sales down 15%), widening GAAP net loss ($0.8M) and a low cash balance (~$0.3M) are significant headwinds. Regulatory uncertainty remains an important risk. Overall, positives (cost discipline, product launches, near cash‑flow breakeven) are counterbalanced by substantial revenue and liquidity challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that the company will prioritize scaling and profitable growth by expanding non‑cannabinoid +PlusHLTH product launches and select international expansion via Cultured Foods while continuing strict cost and working‑capital discipline to drive margins and cash flow. Key metrics referenced: Q2 revenue of $3.0M (down 7% sequential, 17% YoY; unit sales down 15%), gross margin 48.6% (48.9% in Q1; 50.9% year‑ago), SG&A $1.7M (down ~7.9% sequential/~10% YoY), adjusted EBITDA loss $0.1M (flat vs Q1), operating loss $0.3M, net loss $0.8M, positive operating cash flow of ~ $20k in Q2 (also positive in Q1), cash ≈ $0.3M, inventory ≈ $4.0M (vs $4.1M year‑end), and convertible note fair value $1.0M after ~ $0.7M of conversions — with an aim to reach sustainable positive operating cash flow and to remain flexible pending regulatory timing changes (potential delay of Nov 12, 2026 provisions to Dec 11, 2026).
CV Sciences Financial Statement Overview
Summary
Fundamentals are pressured: TTM revenue is down sharply (-25.6%) and the company remains unprofitable (TTM net margin ~-15.7%). Cash generation is weak with negative operating cash flow (-$0.17M) and negative free cash flow (-$0.19M). The balance sheet is a relative positive with moderate leverage (debt-to-equity ~0.80), but ongoing losses increase the risk of renewed balance-sheet pressure.
Income Statement
28NegativeBalance Sheet
44NeutralCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.52M | 13.79M | 15.71M | 16.00M | 16.20M | 20.05M |
| Gross Profit | 6.20M | 6.75M | 7.17M | 7.08M | 5.55M | 8.62M |
| EBITDA | -1.19M | -562.00K | -1.86M | 3.85M | -5.73M | -14.35M |
| Net Income | -1.72M | -958.00K | -2.39M | 3.10M | -8.21M | -15.55M |
Balance Sheet | ||||||
| Total Assets | 6.43M | 6.96M | 7.93M | 26.35M | 12.74M | 18.07M |
| Cash, Cash Equivalents and Short-Term Investments | 308.00K | 278.00K | 454.00K | 1.32M | 611.00K | 1.38M |
| Total Debt | 891.00K | 1.61M | 779.00K | 442.00K | 1.53M | 922.00K |
| Total Liabilities | 4.16M | 5.49M | 6.13M | 23.44M | 13.51M | 14.52M |
| Stockholders Equity | 2.27M | 1.47M | 1.79M | 2.90M | -777.00K | 3.54M |
Cash Flow | ||||||
| Free Cash Flow | -189.00K | -516.00K | -879.00K | 2.25M | -1.89M | -7.52M |
| Operating Cash Flow | -170.00K | -407.00K | -861.00K | 2.25M | -1.89M | -7.49M |
| Investing Cash Flow | -19.00K | -109.00K | -28.00K | -156.00K | 0 | -35.00K |
| Financing Cash Flow | 118.00K | 337.00K | 32.00K | -1.39M | 1.12M | 4.37M |
CV Sciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 44.40 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVSI.
CV Sciences Peers Comparison
Overall Rating
IXHL47Neutral
YCBD43Neutral
CVSI41Neutral
COSM38Underperform
IMCC37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $21.96M | -2.61 | -12.40% | ― | -100.00% | 96.25% | |
| 43Neutral | $4.19M | -1.22 | -34.25% | ― | 10.01% | 95.01% | |
| 41Neutral | $2.35M | -1.11 | -100.85% | ― | -12.88% | -8.75% | |
| 38Underperform | $14.84M | -0.22 | -118.89% | ― | 33.82% | 34.05% | |
| 37Underperform | $813.37K | -0.02 | 528.80% | ― | -35.33% | -110.11% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CVSI | CV Sciences | 0.01 | -0.02 | -64.29% | |
| YCBD | Cbdmd INc | 0.37 | -0.13 | -25.20% | |
| COSM | Cosmos Holdings | 2.95 | -9.52 | -76.35% | |
| IMCC | Im Cannabis Corp | 0.54 | -40.87 | -98.71% | |
| IXHL | Incannex Healthcare Limited Sponsored ADR | 1.75 | -8.21 | -82.42% |
CV Sciences Corporate Events
CV Sciences Reports Third-Quarter Revenue and Positive Adjusted EBITDA
PositiveOn November 12, 2026, CV Sciences reported third-quarter revenue of $3.0 million, down from $3.3 million a year earlier and unchanged from the second quarter. Gross margin increased to 50.0%, operating expenses fell 11.6% year over year to $1.6 milli...
CV Sciences Resolves Legal Dispute, Refocuses on Operations
PositiveCV Sciences reported that it had initiated an arbitration proceeding on February 12, 2025, against its former legal counsel, a dispute that has now concluded. The company has settled the case, receiving $500,000 and entering into a mutual release of...
CV Sciences Reports Q2 Results Amid Regulatory Reprieve
NegativeOn August 13, 2026, CV Sciences reported second-quarter 2026 results showing revenue of $3.0 million, down 17.5% from a year earlier, as restrictive federal and state regulations weighed on sales volumes and reduced units sold by 14.9%. Despite the t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
